TP53 and prostate cancer: FANCI protein expression has already been studied in various cancers, including hepatocellular carcinoma [31], cutaneous melanoma [32] or prostate cancer, in which FANCI silencing reduces proliferation in p53-expressing prostate cancer cells [33].